News

The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m),

Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent into

Results from the trial showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. enzalutamide or abiraterone in men with

As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its

The agreements between GSK and Sabin in this regard are for advancing the development of the prophylactic candidate Ebola vaccines against the Ebola Zaire, Ebola Sudan and the

Dravet syndrome is a severe and progressive genetic epilepsy, characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The effects of the disease

“To help support the long-term health of people living with HIV, it is ideal that treatment regimens deliver both durable viral suppression and a demonstrated tolerability profile,” said

Neoleukin is involved in the creation of next-generation immunotherapies using de novo protein design technology. The company applies advanced computational methods for the designing of proteins, which show

Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce